Companies in #Neuromodulation

CVRx is a commercial-stage medical device company commercializing Barostim, an implantable neuromodulation device that delivers electrical pulses to carotid baroreceptors to restore baroreflex activation therapy for patients with cardiovascular disease, primarily heart failure. Incorporated in 2000, headquartered in Minneapolis, and listed on Nasdaq in June 2021, the company sells through a direct sales force in the US and Germany. Its August 2026 Q2 report showed $15.7 million in revenue with 87% gross margins but a sharp cut to the full-year 2026 revenue outlook, triggering a roughly 60% single-day repricing and downgrades from Lake Street and Craig-Hallum.

Brain neuromodulation and digital therapeutics for migraine and depression. Products include Relivion (FDA-approved for migraine) and ProlivRx. Expanded VA contract for depression treatment.

Theranica is a digital therapeutics company developing FDA-cleared neuromodulation devices for migraine and other neurological conditions. Nerivio, its wearable non-invasive vagus nerve stimulation device, became the first neuromodulation product to reach more than half of the U.S. insured population.